Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
暂无分享,去创建一个
S. Dacic | A. Argiris | C. Belani | W. Gooding | Yongli Shuai | D. Friedland | A. Tarhini | A. Kotsakis | D. Petro
[1] Eric Sauerbrei,et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Simon,et al. Stable Disease Is Not Preferentially Observed With Targeted Therapies and as Currently Defined Has Limited Value in Drug Development , 2009, Cancer journal.
[3] D. Gandara,et al. Phase I evaluation of lapatinib and everolimus in patients with advanced malignancies: Southwest Oncology Group trial S0528. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] F. Hommura,et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[6] Suzanne F. Jones,et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Lane,et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Suzanne F. Jones,et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Donna Niedzwiecki,et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Mary W Redman,et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Hidalgo,et al. A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] M. Fukuoka,et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study , 2007, Investigational New Drugs.
[13] K. Uematsu,et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Edward L Spitznagel,et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] H. Lane,et al. The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 Translation , 2005, Cell.
[16] I. Judson,et al. Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Jett,et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] A. Argiris,et al. Progress in the therapy of small cell lung cancer. , 2004, Critical reviews in oncology/hematology.
[19] H. Lane,et al. Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells , 2004, Cancer Research.
[20] KyungMann Kim,et al. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. , 2003, Lung cancer.
[21] C. Blanke,et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Litz,et al. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. , 2002, Molecular cancer therapeutics.
[23] U. de Faire,et al. Job strain and major risk factors for coronary heart disease among employed males and females in a Swedish study on work, lipids and fibrinogen. , 2002, Scandinavian journal of work, environment & health.
[24] P. Dennis,et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.
[25] A. Argiris,et al. Staging and clinical prognostic factors for small-cell lung cancer. , 2001, Cancer journal.
[26] P. Dennis,et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.
[27] E. Smit,et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[29] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R. A. Robinson,et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[32] J R Anderson,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Wei-Yin Loh,et al. Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..
[34] C. Sessa,et al. mTOR inhibitors in the treatment of cancer. , 2008, Expert opinion on investigational drugs.
[35] C. Harris,et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. , 2003, The Journal of clinical investigation.
[36] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.